Antivascular endothelial growth factor for choroidal neovascularization in pathologic myopia

  • Battaglia Parodi M
  • Iacono P
  • Bandello F
  • 3


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


Choroidal neovascularization (CNV) is the most common vision-threatening macular complication in pathologic myopia (PM) being detectable in 4-11% of the affected eyes. Treatment of PM-related CNV is still controversial. Intravitreal injections of antivascular endothelial growth factor molecules are able to inhibit the vascular endothelial growth factor isoforms and have shown promise in the treatment of myopic CNV. The present review describes the beneficial effects of this approach both for subfoveal and juxtafoveal CNV. However, considering the lack of randomized clinical trials and the relatively short follow-up in most of the studies, a multicentric clinical trial should be necessary to validate the positive results in the long term.

Author-supplied keywords

  • *Angiogenesis Inhibitors/ad [Administration & Dosa

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in


  • M Battaglia Parodi

  • P Iacono

  • F Bandello

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free